Emerald Fund Rebalancing
Emerald Advisers Rebalances Portfolio, Increasing Ollie's Stake While Trimming KalVista and LivaNova Holdings
Anonymous
Key Points
1
Emerald Advisers LLC's LivaNova stake stands at 670,207 shares, about 1.3% of its portfolio, making it the 15th largest holding with a value around $42.6 million.
2
A cluster of smaller funds increased Ollie’s Bargain Outlet positions this quarter, including Cornerstone Planning Group LLC (255 shares, about $27,000), Allworth Financial LP (221 shares, about $28,000), Northwestern Mutual Wealth Management Co. (279 shares, about $31,000), CENTRAL TRUST Co (477 shares, about $44,000) and Maseco LLP opening a new position around $30,000.
3
KalVista Pharmaceuticals shows notable liquidity and leverage metrics: current ratio 5.17, quick ratio 5.10, debt-to-equity 8.18; negative earnings multiple (P/E -7.80) and beta -0.12, with a market cap near $1.44 billion.
4
Ollie's coverage includes analyst commentary: KeyCorp reiterates an overweight rating, while JPMorgan Chase & Co. maintains a neutral rating and lowers its price objective to $70 from $152.
Emerald Advisers LLC boosted its stake in Ollie's Bargain Outlet by 16.3% in Q1 2026, adding 48,543 shares to reach 347,125 shares worth about $31.95 million, according to Watchlist News. At the same time, the Pennsylvania-based firm trimmed its positions in KalVista Pharmaceuticals and LivaNova, signaling a deliberate shift toward consumer retail and away from life sciences.
Together with its subsidiary Emerald Mutual Fund Advisers Trust, the firm manages roughly $7.8 billion in assets. The two funds moved in lockstep this quarter — both buying more Ollie's and selling some KalVista — reflecting a coordinated rebalancing across sectors.
Emerald Doubles Down on Discount Retail as Consumers Cut Back
Ollie's Bargain Outlet sells surplus and closeout goods at steep discounts. It thrives when shoppers feel economic pressure. Emerald's 16.3% stake increase suggests the firm sees that moment now. Emerald Mutual Fund Advisers Trust also raised its Ollie's position by 6.4%, reaching 197,473 shares worth about $18.18 million, according to Watchlist News.
Smaller funds piled in too. Cornerstone Planning Group added shares to reach 255 total (about $27,000). Allworth Financial grew its stake by 301.8% to 221 shares (about $28,000). Northwestern Mutual added shares to hold 279 (about $31,000). Maseco LLP opened a brand-new position near $30,000. Ollie's posted Q1 revenue of $658.93 million — a 14.2% year-over-year jump — and beat earnings estimates of $0.87 with an actual $0.91 per share.
Wall Street Split on Ollie's: JPMorgan Cuts Target in Half
Analysts are sharply divided on Ollie's future. On July 7, 2026, JPMorgan downgraded the stock and slashed its price target from $152 to $70 — less than half its prior estimate. The bank cited margin pressure and a ceiling on low-income consumer spending. KeyCorp, by contrast, kept its "Overweight" rating. Goldman Sachs trimmed its target from $129 to $112 but held its "Buy" call, urging investors to buy the dip.
Loop Capital also maintained a "Buy" with a $135 target. Piper Sandler set a $114 price target after Ollie's Q1 results dropped on June 3. The wide gap between JPMorgan's $70 and Loop Capital's $135 reflects genuine uncertainty about whether trade-down shopping from middle-income consumers can offset cost pressures.
KalVista Stake Cut Before Chiesi's $1.9 Billion Buyout Closed
Emerald Advisers trimmed its KalVista stake by 5.7% in Q1, dropping to 1,264,023 shares worth about $25.45 million. Emerald Mutual Fund Advisers Trust cut its position by 5.8% to 805,762 shares (about $16.22 million). The timing looks deliberate. On April 29, 2026, Chiesi Group — a Parma, Italy-based pharmaceutical company — announced a $1.9 billion all-cash deal to buy KalVista, a 36% premium to its trading price.
KalVista's key product, "Ekterly," is the first pill patients can take on-demand to stop life-threatening swelling attacks caused by Hereditary Angioedema (HAE). Chiesi completed the deal on June 11. Before the buyout closed, KalVista carried a market cap near $1.44 billion, a negative P/E of -7.80, and a current ratio of 5.17 — showing strong short-term liquidity. Other major holders included Vanguard Group, State Street, and Vestal Point Capital, which trimmed its stake by 40,000 shares to 1.85 million shares worth $37.24 million.
LivaNova Trim Comes Despite Strong Earnings and FDA Win
Emerald Advisers sold 30,741 shares of LivaNova in Q1, cutting its stake by 4.4% to 670,207 shares worth about $42.6 million. That makes LivaNova Emerald's 15th largest holding, at 1.3% of its total portfolio. The sale came even as LivaNova reported strong Q1 results on May 6 — adjusted earnings per share of $0.98, beating the $0.91 consensus — on revenues of $362.3 million.
LivaNova also won FDA approval for its aura6000 system, a device that treats moderate-to-severe Obstructive Sleep Apnea (OSA) by stimulating a nerve in the neck. CEO Vladimir Makatsaria called the trial results a sign that "targeted hypoglossal nerve stimulation provides a compelling alternative" to existing therapies. Wall Street currently rates the stock with 7 "Buy" and 4 "Hold" calls. Emerald's trim looks like profit-taking — freeing capital to fund its growing retail bet on Ollie's.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
34
Articles
39
Reach
73
A
AnonymousAuthor